News Powered By:
– a collaborative partner.
CenterWatch : October 20, 2017 1:52 pm : Centerwatch, Clinical Intelligence, Global News, Shionogi
Shionogi & Co. announced it will present positive efficacy and safety results from a global phase III study (L-PLUS 2) of lusutrombopag (S-888711), an investigational, once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting to be held October 20-24 in Washington, D.C. L-PLUS 2 […]
The post Phase III Lusutrombopag study shows positive efficacy appeared first on CenterWatch News Online.
CenterWatch : October 20, 2017 1:44 pm : Centerwatch, Clinical Intelligence, FA, Kite Pharma, United States
The FDA approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the […]
The post FDA approves CAR-T cell therapy for large B-cell lymphoma appeared first on CenterWatch News Online.
CenterWatch : October 20, 2017 1:31 pm : AMRA, BioTelemetry Research, Centerwatch, Global News, R&D Trends
AMRA, the international leader in body composition analysis, and BioTelemetry Research (BTR), a global imaging and cardiac core lab, announced the formation of an exclusive alliance for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) clinical trials. This first-to-market partnership will advance imaging science and benefit clinical trial sponsors in several musculoskeletal and metabolic […]
The post AMRA, BioTelemetry partner on NASH/NAFLD clinical trials appeared first on CenterWatch News Online.
CenterWatch : October 20, 2017 1:28 pm : Accenture, Centerwatch, Global News, Partnership on AI, Technology Solutions
Accenture has joined the Partnership on AI, an alliance of businesses, researchers, academics and policy makers that work to advance the understanding of artificial intelligence (AI) technology and develop best practices on the challenges and opportunities within the field. Accenture joins other prominent industry leaders who share its commitment to advancing the field of AI so […]
CenterWatch : October 20, 2017 1:25 pm : Centerwatch, Global News, Institut Curie, Pierre Fabre, R&D Trends
Institut Curie and the IRPF (Institut de Recherche Pierre Fabre) will collaborate on new therapeutic strategies to advance cancer treatment for patients. The objective of this novel partnership is to dissect the biology of novel therapeutically tractable targets and evaluate the impact of innovative pharmacological approaches leveraging the Institut Curie’s biological models. “We will work […]
The post Institut Curie, Pierre Fabre Partner on immuno-oncology appeared first on CenterWatch News Online.